FeesSafety
Pluang+

Tvardi advances oral STAT3 inhibitor TTI-109 for inflammatory bowel disease after positive FDA pre-IND feedback

Market News
19 Nov 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
Tvardi advances oral STAT3 inhibitor TTI-109 for inflammatory bowel disease after positive FDA pre-IND feedback

Tvardi Therapeutics received constructive FDA feedback on its next-generation oral STAT3 inhibitor, TTI-109, supporting its Phase 2 development for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The FDA agreed the planned nonclinical studies and clinical trial design are appropriate, guiding Tvardi's IND submission expected in 2027. New data suggest TTI-109 selectively inhibits STAT3 with minimal impact on STAT1 and STAT5, potentially offering a safer profile than current JAK inhibitors. The company aims to start Phase 2 trials pending IND clearance and funding availability.

Tvardi Therapeutics' development of the oral STAT3 inhibitor TTI-109 provides context for health sector activity on Pluang as of Nov 19, 2026, 19:13 WIB. Among 150 priced health stocks, 82 rose and 63 fell. Notably, Ginkgo Bioworks Holdings Inc (DNA) rose 4.03% to USD 8.78 with 94% buy orders and a typical hold time of 10 days, contrasting with Haleon plc (HLN), which fell 3.96% to USD 8.72 and Twist Bioscience Corp (TWST), which rose 3.52% to USD 120.44 but saw 69% sell orders and a longer hold time of 28 days.

More News

Bath & Body Works beats earnings and revenue estimates, launches $500M buyback, raises sales outlook.

Bath & Body Works beats earnings and revenue estimates, launches $500M buyback, raises sales outlook.

Bath & Body Works reported third-quarter earnings per share of $0.26, surpassing the $0.12 estimate, and revenue of $1.58 billion, above the $1.55 billion estimate. The company also announced a new $500 million share repurchase program and raised its...

Company Fundamentals
Bullish
52 minutes ago
Pasqal integrates quantum processors natively into Slurm for easier HPC management with NVIDIA support.

Pasqal integrates quantum processors natively into Slurm for easier HPC management with NVIDIA support.

Pasqal has integrated its neutral-atom quantum processors natively into Slurm's Hierarchical Resources (HRES) system, recently expanded by NVIDIA. This allows supercomputing centers to manage quantum processing units (QPUs) alongside CPUs and GPUs mo...

Market News
Bullish
56 minutes ago
SpaceX shifts focus from satellite internet profits to rapid AI growth, trading at a high valuation.

SpaceX shifts focus from satellite internet profits to rapid AI growth, trading at a high valuation.

SpaceX currently earns most of its profits from its Starlink satellite internet service, which has 13.6 million subscribers and generated $2.37 billion in operating income last quarter. However, the company is aggressively pivoting towards artificial...

Market News
Bullish
1 hour ago
TSMC and Applied Materials poised for strong growth amid booming semiconductor demand.

TSMC and Applied Materials poised for strong growth amid booming semiconductor demand.

Despite a recent 25% drop in semiconductor stocks, TSMC and Applied Materials stand out due to their dominant market positions and growth potential. TSMC leads with a 73% share in the foundry market, benefiting from AI chip demand and planned price h...

Market News
Bullish
1 hour ago
Stock market faces sharp correction risk amid AI turmoil and rising interest rates, Buffett advises cautious investing.

Stock market faces sharp correction risk amid AI turmoil and rising interest rates, Buffett advises cautious investing.

The stock market is vulnerable to a sharp correction due to rising interest rates and uncertainty in the AI industry following Nvidia CEO Jensen Huang's departure amid scandal. Inflation pressures have led the Federal Reserve to raise rates, potentia...

Bearish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App